CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
Clinical trials for CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ADZYNMA tracked for safety in rare blood disorder
Disease control Recruiting nowThis study monitors 40 people in Japan with congenital thrombotic thrombocytopenic purpura (cTTP) who are receiving ADZYNMA (recombinant ADAMTS13) as part of their routine care. Researchers will track side effects and check if the drug improves platelet counts and ADAMTS13 activi…
Matched conditions: CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New study tracks safety of adzynma for rare blood clot disorder
Knowledge-focused Recruiting nowThis study looks at the real-world safety of Adzynma, a lab-made protein, in people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder. Researchers will review medical records of about 50 children and adults to see how many develop allergi…
Matched conditions: CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC